Dr. Lane is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
450 Brookline Ave
Boston, MA 02215Phone+1 617-632-3000
Education & Training
Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2008 - 2012- Brigham and Women's HospitalResidency, Internal Medicine, 2006 - 2008
Washington University in St. Louis School of MedicineClass of 2006
Certifications & Licensure
MA State Medical License 2008 - 2025
American Board of Internal Medicine Hematology
Clinical Trials
- SL-401 in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm or Acute Myeloid Leukemia Start of enrollment: 2014 Sep 01
- SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Start of enrollment: 2017 Jun 26
- Study of Venetoclax, a BCL2 Antagonist, for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Start of enrollment: 2018 Aug 23
Publications & Presentations
PubMed
- How I treat blastic plasmacytoid dendritic cell neoplasm.Mohamed A Kharfan-Dabaja, Andrew A Lane, Naveen Pemmaraju
Blood. 2025-02-06 - BPDCN MYB fusions regulate cell cycle genes, impair differentiation, and induce myeloid-dendritic cell leukemia.Christopher A G Booth, Juliette M Bouyssou, Katsuhiro Togami, Olivier Armand, Hembly G Rivas
JCI Insight. 2024-12-20 - Blastic plasmacytoid dendritic cell neoplasm: Extensive disease, Langer lines, and blood burden in a retrospective study of 66 cases.Christopher J Fay, Jesse P Hirner, Shai Shimony, Ai-Tram Bui, Andrew A Lane
Journal of the American Academy of Dermatology. 2024-11-14
Abstracts/Posters
- Clinical Profile of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate (ADC), in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) or Blastic ...Andrew A. Lane, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- A Phase I Study of IMGN632, a Novel CD123-Targeting Antibody-Drug Conjugate, in Patients with Relapsed/Refractory Acute Myeloid Leukemia, Blastic Plasmacytoid Dendriti...Andrew A. Lane, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Efficacy Proof of Concept for Allogeneic CD123 Targeting CAR T-Cells Against Primary Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Efficient Control of Tumor P...Andrew A. Lane, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Join now to see all
Press Mentions
New Target for Potential Leukemia TherapyMay 8th, 2024- Leukemia Relapse Could Be Prevented by Disrupting Immune Signaling MechanismMay 8th, 2024
Stemline Therapeutics Announces That Pivotal Trial of SL-401 in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Meets Primary EndpointOctober 31st, 2017- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
